Pretreatment with P2Y 12 Receptor Inhibitors in Acute Coronary Syndromes—Is the Current Standpoint of ESC Experts Sufficiently Supported? Excessive platelet reactivity plays a pivotal role in the pathogenesis of acute myocardial infarction. Today, the vast majority of patients presenting with... P Niezg...
Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is currently the standard of care for the prevention of ischemic events in patients with acute coronary syndrome or undergoing percutaneous coronary intervention. Several studies have shown that not all patients benefit from the ...
The Impact of Preclinical High Potent P2Y 12 Inhibitors on Decision Making at Discharge and Clinical Outcomes in Patients with Acute Coronary Syndrome Background: Purinergic signaling receptor Y12 (P2Y12) inhibitors are a fundamental part of pharmacological therapy in acute coronary syndrome (ACS) for...
P2Y12inhibitorprasugrelticagrelorGuidelines recommend treatment with a P2Y12 platelet adenosine diphosphate receptor inhibitor in patients undergoing elective or urgent percutaneous coronary intervention (PCI), but the optimal agent or timing of administration is still not clearly specified. The P2Y12 ...
Letter--Prudent Formulary Management or Underutilization of the Novel P2Y12 Receptor Inhibitors in Patients with Acute Coronary Syndrome Who Received Percutaneous Coronary Intervention? DISCLOSURES: The author is a former employee of AstraZeneca and owns stock in AstraZeneca. The author reports no conflic...
CLOPIDOGREL IS THE MOST WIDELY PRESCRIBED PLATElet P2Y12 receptor inhibitor and is recommended, in addition to aspirin, for prevention of atherothrombotic recurrences inpatientswithacutecoronary syndromes (ACS) and for those undergoing percutaneous coronary interventions (PCI). Despite the proven efficacy ...
Aspirin is the foundation antiplatelet agent. New P2Y12 receptor inhibitors (prasugrel and ticagrelor) have clear benefits compared with clopidogrel for dual antiplatelet therapy, and cangrelor or vorapaxar, a thrombin receptor inhibitor, may be of value in specific settings. Anticoagulation uses 1 of ...
Dual antiplatelet therapy is mandated for patients undergoing PCI and typically consists of aspirin and a P2Y12 receptor antagonist. Aspirin hypersensitivity poses a significant clinical dilemma, as the safety and efficacy of oral antiplatelet combinations that exclude aspirin have not been validated. ...
The role of purinergic P2Y12 receptor blockers on the angiogenic properties of endothelial cells: An in vitro study. J. Physiol. Pharmacol. 2018, 69. [CrossRef] 65. Gunduz, D.; Tanislav, C.; Schluter, K.D.; Schulz, R.; Hamm, C.; Aslam, M. Effect of ticagrelor on endothelial ...
The optimal duration of dual antiplatelet therapy(DAPT)of aspirin and a P2Y12 receptor blocker after stenting is still being debated.The current recommendations for DAPT duration are signifi cantly focused on reducing stent thrombosis;a less frequent event with later than earlier generation drug ...